Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. on June 12, 2008. The report details a material definitive agreement regarding a new financing round and a change in the Board of Directors. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics and Capital Structure
- Capital Raised: $500,000 total from a single investor.
- Cash Received: $350,000 received at closing on June 12, 2008.
- Committed Capital: $150,000 to be invested on or before August 15, 2008.
- Share Price: $0.55 per share.
- Warrants Issued: Warrants to purchase up to 318,182 shares at an exercise price of $0.75 per share.
- Put Option Obligation: The Chairman's obligation to invest up to $1,500,000 was reduced to $1,150,000 following the credit of amounts raised in this transaction.
The filing does not provide specific values for revenue, net profit, operating cash flow, gross margins, or total debt levels.
Material Changes
- Financing Agreement: Execution of Amendment No. 7 to the Warrant and Put Option Agreement (originally dated November 30, 2006).
- Put Option Extension: The deadline for the Company to exercise its put option requiring the Chairman to invest additional funds was extended to September 1, 2008.
- Board Composition: Appointment of Kira Sheinerman as a new Director.
Outlook, Risks, and Management Commentary
The filing focuses on securing near-term liquidity through the $500,000 investment and maintaining the option to raise up to $1,150,000 more via the Put Option by September 1, 2008. The appointment of Kira Sheinerman, who holds a Ph.D. in Biomedical Sciences and experience in investment banking for biotech firms, suggests a strategic focus on leveraging expertise in oncology and early-stage biotech development. No specific forward-looking financial guidance or risk factors beyond the standard obligations of the financing agreement are detailed in this text.
Investor Verification Checklist
- Verify the exact number of shares issued for the $350,000 closing payment based on the $0.55 price.
- Confirm the dilution impact of the 318,182 warrants issued at a $0.75 strike price.
- Review the full text of Amendment No. 7 (Exhibit 4.1) to understand specific conditions attached to the remaining $1,150,000 Put Option obligation.
- Check subsequent filings to confirm if the remaining $150,000 investment was received by the August 15, 2008 deadline.